Favorable Interim Data Presented for Tyme’s SM-88 Phase 2 Trial for Prostate Cancer Patients

Favorable Interim Data Presented for Tyme’s SM-88 Phase 2 Trial for Prostate Cancer Patients
Tyme Technologies' SM-88 reduced the levels of circulating cancer cells — an indicator of metastatic disease — in all prostate cancer patients treated in an ongoing Phase 2 trial, according to data revealed at the European Society for Medical Oncology (ESMO) 2017 Congress, in Madrid, Spain. The findings support the potential of SM-88 as a relatively non-toxic alternative to current standard of care — chemotherapy or androgen deprivation therapy (ADT) — in this subset of non-metastatic patients who had rising PSA levels, but no visible tumor. The poster presentation was titled “
Subscribe or to access all post and page content.